Related Experiment Video
Updated: Jun 2, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality
1Denver Nephrologists PC, Denver, Colorado 80230, USA. gablock@denverneph.net
Insights
High phosphorus and FGF-23 levels in chronic kidney disease-mineral and bone disorder (CKD-MBD) correlate with mortality. Interventions targeting CKD-MBD may improve survival, but require randomized trials for confirmation.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Chronic kidney disease-mineral and bone disorder (CKD-MBD) involves complex bone and cardiovascular abnormalities.
- Current research often focuses on surrogate outcomes rather than mortality.
- Understanding CKD-MBD's impact on patient survival is critical.
Purpose of the Study:
- To review recent literature on interventions for CKD-MBD, focusing on mortality as the primary clinical outcome.
- To assess the link between mineral metabolism abnormalities and mortality in CKD patients.
- To evaluate the evidence for interventions impacting CKD-MBD and patient survival.
Main Methods:
- Literature review of recent studies on CKD-MBD interventions.
- Analysis of studies reporting on mortality as a clinical outcome.
- Examination of interventions affecting phosphorus, FGF-23, calcium, and parathyroid hormone levels.
Main Results:
- Elevated serum phosphorus and FGF-23 are linked to increased mortality across all CKD stages.
- Interventions targeting dietary phosphorus and mineral levels support the hypothesis of a direct link to mortality.
- Limited evidence exists from placebo-controlled randomized trials, except for altered dialysis prescriptions.
Conclusions:
- Accumulating observational data suggest therapeutic interventions improve survival in CKD patients with CKD-MBD.
- Interventions include phosphate binders, calcimimetics, and dietary/dialysis modifications.
- Randomized clinical trials are necessary to confirm if CKD-MBD interventions improve hard clinical outcomes.
Purpose Of Review:
Chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses a broad spectrum of abnormalities related to bone and cardiovascular health. Many reports related to therapeutic interventions specifically aimed at these disorders describe an effect only on surrogate outcomes. This review will focus on recent literature pertaining to interventions directed at CKD-MBDs that emphasize the clinical outcome of mortality.
Recent Findings:
Higher levels of serum phosphorus (including those within the normal range) and its regulatory hormone, fibroblast growth factor 23 (FGF-23), are associated with increased mortality in patients with all stages of CKD. Reports investigating specific interventions that affect dietary intake of phosphorus, as well as serum levels of phosphorus, FGF-23, calcium, and parathyroid hormone have recently been published which support the hypothesis that abnormal mineral metabolism is directly linked to increased mortality. Unfortunately, with the exception of altered dialysis prescription, no intervention has been subject to the scrutiny of placebo-controlled randomized clinical trials.
Summary:
Observational evidence continues to accumulate relating specific therapeutic interventions to improved survival in patients with kidney disease including phosphate binders, calcimimetics, and altered dietary and dialysis prescription patterns. It is time for randomized clinical trials to definitively establish whether or not interventions directed at CKD-MBD effect improvement in hard clinical outcomes in patients with kidney disease.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management